Zantrene works.
Zantrene has been approved in the past in France (for AML) & people are alive still today only because of receiving it in last- ditch treatment for dire relapsed/ refractory acute myeloid leukaemia.
The 2 particular women who have been followed up by their doctors through decades, and are without doubt fully cured and living normal lives over 30 years later, + even been able to have multiple children each— are alive because they were then able to successfully receive and survive matching bone marrow transplantation including autologous. After going into remission from their acute, difficult to treat leukaemias,& having failed all possible other treatments and relapsed - they otherwise would have died within a short time over 3 decades ago. Harrowing at the time.
ie. They were very very lucky - but Zantrene got them into remission fully.
Zantrene got many more children back then with refractory AML into remission(40% + ?) , but unfortunately most did not have chance to receive an exact matching possible bone marrow from donor siblings.
A bone marrow transplantation donor was not available in the majority of cases nor always survived back then.
(Which would no longer be a problem - back then odds were 1 in 2 or even only 1 in 3 chance of an exact match in a direct sibling, parents and aunts/ uncles etal insufficient. A stem cell transplant or a bone marrow donation is nearly always possible now,& successfully survived as procedure- if can gain treatment for the blood cancer & achieve a remission or partially. Obviously this is only wrt leukaemia not cancers Zantrene can have efficacy against , Zantrene was past approved for acute myeloid leukaemia )
I know I am repeating old information, but Zantrene has base value in AML.
And much bigger again now if mechanism of action proven for targeted treatment.
Hence the under the radar etc which lead to our long marking time with shareprice.
And capital markets are now tight and research and full investigation funding is best undertaken in a major company?
The biggest thing is the fact that Zantrene also does not harm the heart and indeed seems to protect the heart & cardiac cells from harm, from other standard of care oncology drug treatments, which all are cardio- toxic.
Dr T suspected prior to joining RAC that there is a protective effect, probably from the meticulous data preserved from the extensive trials, over 60 clinical trials in the past including phase 3.
The medical scientists wrote a lot of notes it seems.
I think respect to our medical researchers now.
Dr T has an excellent choice qualified CSO/ CMO who has commercialised drugs previously.
In many ways this is Daniels baby, but he is so invested and the team needs to be able to proceed and work and take credit and they’re at the coalface.
Our CSO knows how tough big Pharma can be in delineating priorities & I think this is focus, important marketing now , in this sweet spot management think(?) for likely acquisition even now or partnership.
*The ultimate owner would want to be in charge of complete trials and research wrt FTO mechanism of action and determining. (?)
They would want to be directly involved & more in charge. This is what I think we are seeing. (?)
If a takeover though, obviously the majority of shareholders then must approve and accept the price and terms.
Hope makes some sense.
I really don’t like spills either but have seen this occur previously. Upsetting for those of us who really respect and know how much the board member worked for all & how passionate they are, and their knowledge.
On one occasion the very loved medical scientist, who had worked on the treatment and in research for many years, in a company was a final deal negotiator in a share I held, and it wasn’t the best shareprice outcome for shareholders that could have been.
They were very invested and most so with the science & for all to totally go forth.
The big acquiring company executives are thinking of the development & funds required & are focused on big and niche markets & trumping existing treatments or securing treatment pipelines for the future to join their stable. Synergy & good value-adding for the major company they work for.
Thoughts not well- expressed apologies
I think we have got to really be in the market from now on however. I really want the best outcome also and realise how much this could be worth.
Expand
. I actually hadn't ready about the other children but have heard the story multiple times about the two woman which is a great result for them. It is unfortunate that even with remission you may not have a matching bone marrow donor.
(20min delay)